This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in HIV-1 infected particip

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement.

This is a Phase 2, open label, multicenter, study evaluating the efficacy and safety of an active drug in relapsed or refractory subjects with CLL harboring 17p13 (TP53 locus) deletion.

The purpose of this study is to evaluate the efficacy and safety of co-administration of an active drug/an active drug plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrho

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of an active drug, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for an active drug when administered as mono

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of an active drug.

The study will determine the recommended Phase 2 dose (RP2D) of an active drug administered as monotherapy and in combination with an active drug as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of an active drug alone a

This is a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in subjects with relapsed or refractory multiple myeloma who are considered sensitive

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of an active drug alone or when added to ruxolitinib in participants with myelofibrosis.

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of an active drug monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of an act